Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

NCT01405079 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

222

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Gefitinib
DRUG: Vinorelbine+Cisplatin

Sponsor

Guangdong Association of Clinical Trials

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]